Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8 billion bet on mRNA drugs with China’s Abogen Biosciences; and could Sarepta Therapeutics turn things around from last year’s annus horribilis?
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.